UNSPSC 51111851: Histrelin

This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H50H3S3W74. European Medicines Agency schedules Histrelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08046MIG. Histrelin generally arises in the molecular formula C66H86N18O12.

The term HISTRELIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) HISTRELIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule histrelin under HS 29371900 and SITC 54154. As of Q4 2014, HISTRELIN remains the US FDA Preferred Term for this commodity. Histrelin bears US NLM identifiers UMLS ID C0121902 and NCI Concept Code C74270.

UNSPSC 51111851 Histrelin is a Commodity code covering a synthetic gonadotropin-releasing hormone agonist used in treatment of advanced prostate cancer, endometriosis, and precocious puberty. State and local governments procure this pharmaceutical through their health and human services agencies, corrections departments, and school district health clinics. The drug is dispensed as a subcutaneous implant or injection and is typically acquired through state Medicaid programs, prison health services, and public health authority formularies. Purchasing entities source histrelin via competitive bidding against other hormone agonists in the same therapeutic class, often bundled with broader oncology or women's health medication acquisitions.

The source provided contains no recent state or local contract opportunities for histrelin. Without access to posted RFPs, RFQs, IFBs, or ITBs naming this code, geographic concentration and issuing-body patterns cannot be established from current procurement activity. Histrelin procurement is driven by state Medicaid reimbursement policy, drug formulary decisions, and negotiated rates with pharmaceutical suppliers — activity that may be captured under broader pharmaceutical-services codes or handled through state health department contracts rather than standalone commodity solicitations. Business development professionals should monitor state Medicaid procurement offices and health authority RFPs for specialty pharmaceutical acquisitions where histrelin may be specified or bundled.